Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $79.00

by · The Markets Daily

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) had its target price upped by investment analysts at Robert W. Baird from $75.00 to $79.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price objective would suggest a potential upside of 96.27% from the stock’s current price.

DFTX has been the subject of a number of other research reports. Bank of America began coverage on Definium Therapeutics in a report on Tuesday, August 18th. They set a “buy” rating and a $75.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of Definium Therapeutics in a research report on Monday. Wells Fargo & Company lifted their price objective on shares of Definium Therapeutics from $68.00 to $72.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. Needham & Company LLC reissued a “buy” rating and issued a $66.00 price objective on shares of Definium Therapeutics in a report on Monday. Finally, Maxim Group set a $55.00 price objective on shares of Definium Therapeutics and gave the company a “buy” rating in a report on Friday, August 14th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Definium Therapeutics presently has a consensus rating of “Buy” and an average price target of $63.60.

Check Out Our Latest Report on Definium Therapeutics

Definium Therapeutics Stock Up 3.5%

NASDAQ:DFTX opened at $40.25 on Tuesday. Definium Therapeutics has a 52-week low of $8.77 and a 52-week high of $49.70. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. The stock has a 50-day simple moving average of $42.92 and a 200 day simple moving average of $30.49. The company has a market cap of $5.41 billion, a PE ratio of -11.73 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). On average, sell-side analysts expect that Definium Therapeutics will post -3.02 EPS for the current fiscal year.

Insider Buying and Selling at Definium Therapeutics

In related news, insider Mark Sullivan sold 13,008 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $585,750.24. Following the sale, the insider directly owned 320,571 shares in the company, valued at $14,435,312.13. This represents a 3.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Robert Barrow sold 19,023 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $37.94, for a total transaction of $721,732.62. Following the sale, the chief executive officer owned 1,494,640 shares of the company’s stock, valued at approximately $56,706,641.60. This trade represents a 1.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 67,119 shares of company stock valued at $2,887,496. 2.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of DFTX. Nykredit A S acquired a new position in shares of Definium Therapeutics during the second quarter valued at about $45,000. Allworth Financial LP acquired a new position in Definium Therapeutics during the 2nd quarter valued at about $110,000. Integrated Wealth Concepts LLC acquired a new position in Definium Therapeutics during the 2nd quarter valued at about $159,000. NewEdge Advisors LLC bought a new stake in Definium Therapeutics during the 2nd quarter worth approximately $222,000. Finally, WINTON GROUP Ltd purchased a new stake in shares of Definium Therapeutics in the second quarter worth approximately $240,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Key Stories Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

  • Positive Sentiment: Second Phase 3 success: Definium said its Panorama Phase 3 study met its primary endpoint, showing a statistically significant improvement in anxiety symptoms among patients with GAD. Management characterized the data as unusually strong, driving reports of a sharp gain in DFTX shares. Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study
  • Positive Sentiment: Commercial and regulatory expectations improved: Success in a second late-stage GAD trial reduces clinical-development risk and may support Definium’s plans to advance DT120 ODT toward regulatory submission. The results also increased investor interest in the company’s broader psychedelics-focused pipeline. Definium’s LSD-based anxiety, depression drug scores another trial win
  • Positive Sentiment: Analyst support: HC Wainwright reaffirmed its “buy” rating with a $70 price target, while Needham maintained its “buy” rating and set a $66 target. Both targets imply substantial potential upside from the reference price, reinforcing the bullish reaction. Analyst rating reports
  • Neutral Sentiment: News-driven volatility: Trading was briefly halted while investors awaited the clinical update, underscoring the event’s significance and DFTX’s elevated volatility. The company also granted options to three new employees covering 56,650 shares, a relatively modest potential source of dilution. Definium Therapeutics Announces New Employee Inducement Grants
  • Negative Sentiment: Bearish options activity: Traders purchased 6,567 put options, about 68% above typical daily volume. This may reflect hedging after the stock’s rally or concern about elevated valuation and future volatility, although it does not necessarily indicate a directional bet.

About Definium Therapeutics

(Get Free Report)

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

Featured Stories